Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PELI1 | Q96FA3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11873464 | 0.80 | SMN1; SMN2 (0.48) | ALDH1A1KMT2ASMN1; SMN2LMNAKDM4E | |
| SCHEMBL11873455 | 0.80 | SMN1; SMN2 (0.48) | ALDH1A1KMT2ASMN1; SMN2LMNAKDM4E | |
| SCHEMBL524069 | 0.76 | TAS1R3 (0.41) | TAS1R3TAS1R1NAMPTALDH1A1SMN1; SMN2 | |
| SCHEMBL10148831 | 0.76 | TAS1R3 (0.41) | TAS1R3TAS1R1NAMPTALDH1A1SMN1; SMN2 | |
| SCHEMBL18229944 | 0.76 | TAS1R3 (0.41) | TAS1R3TAS1R1NAMPTALDH1A1SMN1; SMN2 | |
| SCHEMBL15846049 | 0.74 | TAS1R3 (0.45) | TAS1R3TAS1R1NAMPTALDH1A1KMT2A | |
| SCHEMBL27353786 | 0.74 | TAS1R3 (0.60) | TAS1R3TAS1R1NAMPTALDH1A1KMT2A | |
| SCHEMBL11680051 | 0.74 | ALDH1A1 (0.44) | ALDH1A1KMT2ALMNAKDM4E | |
| SCHEMBL23750710 | 0.73 | TAS1R3 (0.41) | TAS1R3TAS1R1NAMPTALDH1A1KMT2A | |
| SCHEMBL11874523 | 0.73 | L3MBTL1 (0.38) | NAMPTALDH1A1KMT2ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10772822-B2 | Molecularly imprinted polymers and their use as antidandruff agents | L'OREAL (FR) | 2020-09-15 | — | — | US | disclosed |
| EP-2938641-B1 | MOLECULARLY IMPRINTED POLYMERS AND THEIR USE AS ANTIDANDRUFF AGENTS | ORÉAL L (FR) | 2016-08-24 | — | — | EP | disclosed |
| US-20150342859-A1 | MOLECULARLY IMPRINTED POLYMERS AND THEIR USE AS ANTIDANDRUFF AGENTS | L'OREAL (FR) | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10772822-B2 | Molecularly imprinted polymers and their use as antidandruff agents | DNMT1, POLR1C, ETF1 | TAS1R3 876/4885TAS1R1 921/4885NAMPT 2120/4885 |
| US-20150342859-A1 | MOLECULARLY IMPRINTED POLYMERS AND THEIR USE AS ANTIDANDRUFF AGENTS | DNMT1, POLR1C, ETF1 | TAS1R3 876/4885TAS1R1 921/4885NAMPT 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.